百家乐怎么玩-澳门百家乐官网娱乐城网址_网上百家乐是不是真的_全讯网888 (中国)·官方网站

Beneficiaries

22 Dec 2019

Safeguarding well-being through biomedical science - Named Professorship Scheme promotes excellence in research

Technological innovation holds great promise for the medical field, and one of the top scientists at CityUHK is dedicated to bridging these two domains.

Professor Michael Yang Mengsu

Yeung Kin Man Chair Professor of Biomedical Sciences
Senior Vice-President (Innovation and Enterprise)
Director (Tung Biomedical Sciences Centre)
Director (Biotechnology & Health Centre)

Full Story

Professor Michael Yang Mengsu, Yeung Kin Man Chair Professor of Biomedical Sciences, is seeking to improve people’s lives by converting his research into clinical applications.

“The ultimate goal of biomedical research is to contribute to human well-being. We hope to encourage more students to find and develop their passions for research and innovation and cultivate an entrepreneurial mindset for the challenge of converting CityUHK’s many high-quality research projects into clinical applications that benefit society,” Professor Yang said.

Professor Yang’s research activities focus on the study of the biological processes involved in cancer and the development of biochip technology and nanotechnology for molecular diagnostics and therapeutic applications. He has published more than 200 peer-reviewed papers, received 30 US / China patents and co-founded three spin-off biotech companies since joining CityUHK in 1994. He was awarded the Chunhui Scholar Award by the Ministry of Education in China in 2003, the K. C. Wong Foundation Award in 2004, the Shenzhen Science and Technology Innovation Award in 2006, the Hong Kong Technological Achievement Grand Award in 2007, the Natural Science Award by the Ministry of Education in 2015, and the Wuxi AppTech Life Science and Chemistry Award in 2016.

His latest work won a Gold Medal for a microfluidicsbased technology platform for disease diagnosis and drug screening at the 47th International Exhibition of Invention of Geneva in Switzerland in April 2019. The microfluidic chips can be used for the sensitive detection of multiple gene mutations on barcoded microbead arrays.

This process enables the early identification of infectious pathogens and tumour cells. The platform can also be used to generate arrays of single cells and tumour spheroids for screening the most efficient anti-cancer drugs with their optimal dosages. The patented technology has been licensed to a CityUHK spin-off company that was co-founded recently by three PhD students who graduated from Professor Yang’s laboratory.

Microfluidics Array Technology with Nano-Amplification for Drug Screening and Molecular Diagnosis
“Microfluidics Array Technology with Nano-Amplification for Drug Screening and Molecular Diagnosis”, developed by a research team led by Professor Michael Yang Mengsu.

 

Professor Yang has already turned several research projects into clinical applications. His group previously developed DNA chip technology for the early detection of cervical cancer. That application has been commercialised by a Shenzhen-based company co-founded in 2004 by one of his PhD graduates. Millions of women have benefited from the breakthrough. In addition, a company he helped establish with a PhD graduate and a post-doctoral fellow in Hong Kong in 2010 provides pharmacogenomics and assessment services for side effects from drugs and then suggests relevant preventive measures.

He thanked Dr Yeung Kin-man for supporting the Named Professorship Scheme. With the support of donors, this new scheme aims to promote excellence in research and professional education in the University’s distinguished research areas.

Dr and Mrs Yeung Kin-man
Dr and Mrs Yeung Kin-man at the donation ceremony in 2015. Dr Yeung’s donation supports University’s strategic developments and is used to establish Yeung Kin-man Chair Professorships in the University’s distinguished areas. In addition to biomedical sciences, the areas include
finance, IT innovation and management, media art and neuroscience.

 

These areas include architecture, behavioural and policy sciences, biomedical sciences, data science, data engineering, energy and environment, engineering, environmental veterinary medicine, finance, international economics, information engineering, IT innovation and management, media art, nanomaterials, neuroscience, nuclear engineering, translational neuroscience, and One Health.

“Donations have enabled my students and me to carry out pioneering biomedical research and innovations. We will continue to work hard to develop new technologies that benefit more and more people,” he said.

Research in CityUHK Biomedical Sciences brings new hope and opportunities


In addition to Professor Yang’s efforts to improve people’s lives by converting his research into clinical applications, faculty in CityUHK’s Department of Biomedical Sciences are dedicated to contributing to human betterment through their pioneering research. Associate Professor Dr Yao Xi developed a world-first, self-healable, anti-smudge coating, which enhances medical and aerospace equipment (details); Assistant Professor Dr Chow Kwan-ting studied rare cells that provide insights into developing cancer immunotherapy (details); and Assistant Professor Dr Ban Ki-won developed the first dual stem cell therapy for cardiac repair (details). These research achievements in biomedical science bring new hope and promise new opportunities for safeguarding human well-being.

棋牌| 德州扑克术语| 信誉百家乐博彩网| 菲律宾太阳城网| 巴黎百家乐官网地址| 百家乐三国| 大发888娱乐城游戏lm0| 百家乐官网7scs娱乐场| 女神百家乐官网的玩法技巧和规则 | 百家乐平台那家好| 姚记娱乐城官网| 百家乐最低投注| 百家乐官网高档筹码| 百家乐赌术大揭秘| 清河县| 大发888游戏是真的么| 百家乐最佳投注法下载| 百家乐官网的赚钱原理| 百家乐天下第一缆| 游戏机百家乐下载| 百家乐官网出庄的概率| 顶旺娱乐| 百家乐平注法到656| 百家乐官网视频连连看| 太阳城网上| 百家乐牌机的破解法| 开心8百家乐官网娱乐城| 百家乐赌台| 百家乐官网赌场详解| 墨江| 大发888下载安装| 网络百家乐棋牌| 电子百家乐官网打法| 百家乐官网园搏彩论坛| 黄金岛棋牌游戏下载| 贝博百家乐的玩法技巧和规则 | 最新百家乐双面数字筹码| 豪华百家乐官网人桌| 千亿娱乐| 百家乐网上娱乐场开户注册| 线上百家乐官网怎么玩|